Advertisement

The chemistry of platinum antitumour agents

  • M. J. Abrams

Abstract

The vast majority of clinically used antitumour drugs are either synthetic or natural product based organic compounds. The platinum antitumour agents are unique in that they are coordination complexes. The parent compound of this class, cis-diamminedichloroplatinum(II) (cisplatin), contributes to the curative treatment of testicular teratoma and has significant activity against ovarian, head and neck, bladder, cervical and lung cancers. The compound is also highly toxic with the list of side effects including renal damage, severe nausea and vomiting, myelosuppression, ototoxicity and neurotoxicity. Since the antitumour properties of cisplatin were reported by Rosenberg and coworkers in 1969, well over 1000 platinum analogues have been tested for antitumour activity1,2. The goal of this work has been to find analogues with reduced toxicity and/or wider spectrum of activity. Active cisplatin analogues are generally neutral platinum complexes containing two ammine (NH3) or amine ligands in a cis configuration in concert with two (for Pt(II) analogues) or four (for Pt(IV) compounds) relatively labile halide or oxygen ligands3. Complexes with amine groups in a trans configuration are invariably inactive4. Structure-activity relationships (in animal tumour models) and the clinical aspects of platinum drugs have been reviewed2–6.

Keywords

Trans Isomer Platinum Complex Platinum Drug Alkali Metal Salt Sodium Diethyldithiocarbamate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    B. Rosenberg, L. Van Camp. J.E. Trosko and V.H. Mansour, Nature 222 (1969) 385.CrossRefGoogle Scholar
  2. 2.
    J.C. Dabrowiak and W.T. Bradner, Prog. Med. Chem. 24 (1987) 129.CrossRefGoogle Scholar
  3. 3.
    A. Pasini and F. Zunino, Angew. Chem. Int. Ed. Engl. 26 (1987) 615.CrossRefGoogle Scholar
  4. 4.
    B. Rosenberg, Cancer 55 (1985) 2303.CrossRefGoogle Scholar
  5. 5.
    W.C. Rose, J.E. Shurig, J.B. Huftalen and W.T. Bradner, Cancer Treat. Rep. 66 (1982) 135.Google Scholar
  6. 6.
    C.F.J. Barnard, M.J. Cleare and P.C. Hydes, Chem. Brit. 22 (1986) 1001.Google Scholar
  7. 7.
    A. Werner, Z. Anorg. Chem. 3 (1893) 267.Google Scholar
  8. 8.
    G.B. Kauffman and D.O. Cowan, Inorg. Synth. 1 (1963) 239.CrossRefGoogle Scholar
  9. 9.
    V.V. Lebedinskii and V.A. Golovnya, Izv. Sektora Platiny Drug Blagorod. Metal., Inst. Obshch. Neorg. Khim. Akad. Nauk. S.S.S.R 20 (1947) 95.Google Scholar
  10. 10.
    J.W. Reishus and D.S. Martin Jr., J. Am. Chem. Soc. 83 (1961) 2457.CrossRefGoogle Scholar
  11. 11.
    S.C. Dhara, Indian J. Chem. 8 (1970) 193.Google Scholar
  12. 12.
    G. Raudaschl, B. Lippert, J.D. Hoeschele, H.E. Howard-Lock, C.J.L. Lock and P. Pilon, Inorg. Chim. Acta 106 (1985) 141.CrossRefGoogle Scholar
  13. 13.
    G.H.W. Milburn and M.R. Truter, J. Chem. Soc. (A) (1966) 1609.Google Scholar
  14. 14.
    K. Nakamoto, P.J. McCarthy, J. Fujita, R.A. Condrate and G.T. Behnke, Inorg. Chem. 4 (1965) 36.CrossRefGoogle Scholar
  15. 15.
    J.R. Perumareddi and A.W. Adamson, J. Phys. Chem. 72 (1968) 414.CrossRefGoogle Scholar
  16. 16.
    F. Macdonald and P.J. Sadler, in Biochemical Mechanisms of Platinum Antitumour Drugs, eds. D.C.H. McBrien and T.F. Slater, IRL Press, Oxford (1986) p. 199.Google Scholar
  17. 17.
    N.S. Kurnakov, J. Russ. Phys. Chem. Soc. 25 (1893) 565.Google Scholar
  18. 18.
    F. Basolo, M. Lederer, L. Ossicini and K.H. Stephen, J. Chromatogr. 10 (1963) 262.CrossRefGoogle Scholar
  19. 19.
    F. Aprile and D.S. Martin Jr., Inorg. Chem. 1 (1962) 551.CrossRefGoogle Scholar
  20. 20.
    C. Barnard, Unpublished results.Google Scholar
  21. 21.
    K.W. Lee and D.S. Martin Jr, Inorg. Chim. Acta 17 (1976) 105.CrossRefGoogle Scholar
  22. 22.
    M.C. Lim and R.B. Martin, J. Inorg. Nucl. Chem. 38 (1976) 1911.CrossRefGoogle Scholar
  23. 23.
    T.G. Appleton, R.D. Berry, C.A. Davis, J.R. Hall and H.A. Kimlin, Inorg. Chem. 23 (1984) 3514.CrossRefGoogle Scholar
  24. 24.
    C.J.L. Lock, in Inorganic Chemistry in Biology and Medicine, ed. A.E. Martell, ACS Symp. Ser. Vol. 140 (1980) p. 209.Google Scholar
  25. 25.
    B. de Castro, T.J. Kistenmacher and L.G. Marzilli, Agents Actions Suppl. 8 (1981) 435.Google Scholar
  26. 26.
    S.E. Sherman and S.J. Lippard, Chem. Rev. 87 (1987) 1153.CrossRefGoogle Scholar
  27. 27.
    C.A. McAulliffe and S.H. Murray, Inorg. Chim. Acta Rev. 6 (1972) 103.CrossRefGoogle Scholar
  28. 28.
    R.F. Borch and M.E. Pleasants, Proc. Natl. Acad. Sci. USA 16 (1979) 6611.CrossRefGoogle Scholar
  29. 29.
    V.M. Richon. N. Schulte and A. Eastman, Cancer Res. 41 (1987) 2056.Google Scholar
  30. 30.
    B. Odenheimer and W. Wolf, Inorg. Chim. Acta 66 (1982) L41.CrossRefGoogle Scholar
  31. 31.
    P.T. Daley-Yates and D.C.H. McBrien, Biochem. Pharmacol. 33 (1984) 3063.CrossRefGoogle Scholar
  32. 32.
    J.L. Aull, R.L. Allen, A.R. Bapat, H.H. Daron, M.E. Friedman and J.F. Wilson, Biochem. Biophys. Acta 571 (1979) 352.Google Scholar
  33. 33.
    P.T. Daley-Yates and D.C.H. McBrien, Chem. Biol. Interact. 40 (1982) 325.CrossRefGoogle Scholar
  34. 34.
    S.L. Gonias and S.V. Pizzo, J. Biol. Chem. 258 (1983) 5764.Google Scholar
  35. 35.
    S.V. Pizzo, M.W. Swaim, P.A. Roche and S.L. Gonias, J. Inorg. Biochem. 33 (1988) 67.CrossRefGoogle Scholar
  36. 36.
    M.E. Howe-Grant and S.J. Lippard, in Metal Ions in Biological Systems, ed. H. Sigel, Marcel Dekker, New York (1980) p. 63.Google Scholar
  37. 37.
    A.J. Zelazowski, J.S. Garvery and J.D. Hoeschele, Arch. Biochem. Biophys. 229 (1984) 246.CrossRefGoogle Scholar
  38. 38.
    P.C. Dedon, R. Qazi and R.F. Borch, in Biochemical Mechanisms of Platinum Antitumour Drugs, eds. D.C.H. McBrien and T.F. Slater, IRL Press, Oxford (1986) p. 199.Google Scholar
  39. 39.
    D.L. Bodenner, P.C. Dedon, P.C. Keng and R.C. Borch, Cancer Res. 46 (1986) 2745.Google Scholar
  40. 40.
    H. Iwabuchi, H. Nagashima and K. Nakamura, Bunseki Kagaku 37 (1988) 88.CrossRefGoogle Scholar
  41. 41.
    N. Jain, T.S. Srivastava, K. Satymoorthy and M.P. Chitnis, J. Inorg. Biochem. 33 (1988) 1.CrossRefGoogle Scholar
  42. 42.
    W.I. Sundquist, K.J. Ahmed, L.S. Hollis and S.J. Lippard, Inorg. Chem. 26 (1987) 1524.CrossRefGoogle Scholar
  43. 43.
    V. Savdek, H. Pivcova, D. Noskova and J. Drobnik, J. Inorg. Biochem. 24 (1985) 13.CrossRefGoogle Scholar
  44. 44.
    T.S. Elleman, J.W. Reishus and D.S. Martin Jr., J. Am. Chem. Soc. 80 (1958) 536.CrossRefGoogle Scholar
  45. 45.
    M.J. Abrams, C.M. Giandomenico, J.F. Vollano and D.A. Schwartz, Inorg. Chim. Acta 131 (1987) 3.CrossRefGoogle Scholar
  46. 46.
    P.D. Braddock, T.A. Connors, M. Jones, A.R. Khokhar, D.H. Melzack and M.L. Tobe, Chem.-Biol. Interact. 11 (1975) 145.CrossRefGoogle Scholar
  47. 47.
    K.R. Harrap, M. Jones, C.R. Wilkinson, H. McD. Clink, S. Sparrow, B.C.V. Mitchley, S. Clarke and A. Veasey, in Cisplatin: Current Status and New Developments, eds. A.W. Prestayko, S.T. Crooke and S.K. Carter, Academic Press, New York (1980) p. 193.Google Scholar
  48. 48.
    M.J. Cleare, J.D. Hoeschele, B. Rosenberg and L. Van Camp, U.S. Patent. 4,140,707, 1979.Google Scholar
  49. 49.
    R.C. Harrison, C.A. McAuliffe and A.M. Zaki, Inorg. Chim. Acta 46 (1980) L15.CrossRefGoogle Scholar
  50. 50.
    A. Pasini and C. Caldirola, Inorg. Chim Acta 151 (1988) 19.CrossRefGoogle Scholar
  51. 51.
    S. Neidle. I.M. Ismail and P.J. Sadler, J. Inorg. Biochem. 13 (1980) 205.CrossRefGoogle Scholar
  52. 52.
    Y.W. Cheung. J.C. Cradock. B.R. Vishnuvajjala and K.P. Flora, Am. J. Hosp. Pharm. 44 (1987) 124.Google Scholar
  53. 53.
    L. Canovese, L. Cattalini, G. Chessa and M.L. Tobe. J. Chem. Soc., Dalton Trans. (1988) 2135.Google Scholar
  54. 54.
    J.J. Roberts, R.J. Knox, F. Friedlos and D.A. Lydall, in Biochemical Mechanisms of Platinum Antitumor Drugs, eds. D.C.H. McBrien and T.F. Slater, IRL Press, Oxford (1986) p. 29.Google Scholar
  55. 55.
    S.J. Harland, D.R. Newell, Z.H. Siddik, R. Chadwick, A.H. Calvert and K.R. Harrap, Cancer Res. 44 (1984) 1693.Google Scholar
  56. 56.
    S. Mong, C.H. Huang, A.W. Prestayko and S.T. Crooke, Cancer Res. 40 (1980) 3318.Google Scholar
  57. 57.
    M.J. Cleare and J.D. Hoeschele, Bioinorg. Chem. 2 (1973) 187.CrossRefGoogle Scholar
  58. 58.
    D.R. Alston, T.H. Lilley and J.F. Fraser, J. Chem. Soc. Chem. Commun. 22 (1985) 1600.CrossRefGoogle Scholar
  59. 59.
    D.R. Alston, A.M.Z. Slawin, J.F. Fraser and D.J. Williams, J. Chem. Soc. Chem. Commun. 22 (1985) 1602.CrossRefGoogle Scholar
  60. 60.
    G. Hortobagyi, F. Holmes, D. Frye, V. Hug and G. Fraschini, Proc. Am. Assoc. Cancer Res. 28 (1987) 198.Google Scholar
  61. 61.
    C.F.J. Barnard, P.C. Hydes, W.P. Griffiths and O.S. Mills, J. Chem. Res. (S) (1983) 302.Google Scholar
  62. 62.
    E. Smith and A.H.W. Nias, Br. J. Radiol. 59 (1986) 189.CrossRefGoogle Scholar
  63. 63.
    J.W. Cowens, F.A. Stevie, J.L. Alderfer, G.E. Hansen, L. Pendyala and P.J. Creaven, Int. J. Mass Spectrom. Ion Phys. 48 (1983) 177.CrossRefGoogle Scholar
  64. 64.
    J.F. Vollano, E.E. Blatter and J.C. Dabrowiak, J. Am. Chem. Soc. 106 (1984) 2732.CrossRefGoogle Scholar
  65. 65.
    E.E. Blatter, J.F. Vollano, B.S. Krishnan and J.C. Dabrowiak, Biochemistry 23 (1984) 4817.CrossRefGoogle Scholar
  66. 66.
    L. Pendyala, L. Cowens and S. Madajewicz, in Platinum Coordination Complexes in Chemotherapy, eds. M.P. Hacker. E.B. Douple and I.R. Krakoff, Martinus Nijhoff, Boston, MA (1984) p. 114.Google Scholar
  67. 67.
    J.L. Van der Veer, A.R. Peters and J. Reedijk, J. Inorg. Biochem. 26 (1986) 137.CrossRefGoogle Scholar
  68. 68.
    J.H. Burchenal, K. Kalaher, K. Dew, L. Lokys and G. Gale, Biochimie 60 (1978) 961.CrossRefGoogle Scholar
  69. 69.
    A. Eastman and S. Illenye, Cancer Treat. Rep. 68 (1984) 1189.Google Scholar
  70. 70.
    J.F. Vollano, S. Al-Baker, J.C. Dabrowiak and J.E. Schurig, J. Med. Chem. 30, (1987) 716.CrossRefGoogle Scholar
  71. 71.
    Y. Kidani, K. Inagaki, M. Iigo, A. Hoshi and K. Kuretani, J. Med. Chem. 21 (1978) 1315.CrossRefGoogle Scholar
  72. 72.
    R. Saito and Y. Kidani, Chem. Lett. (1976) 123.Google Scholar
  73. 73.
    P. Schwartz, S.J. Meischen, G.R. Gale, L.M. Atkins, A.B. Smith and E.M. Walker Jr., Cancer Treat. Rep. 61 (1977) 1519.Google Scholar
  74. 74.
    D.P. Kelsen, H. Scher, N. Alcock, B. Leyland-Jones, A. Donner, L. Williams, G. Greene, J.H. Burchenal, C. Tan, F.S. Philips and C.W. Young, Cancer Res. 42 (1982) 4831.Google Scholar
  75. 75.
    P.J. Andrulis Jr., J. Biswas, A. Troy and P. Andrulis III, in Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, ed. M. Nicolini, Martinus Nijhoff, Boston, MA (1988) p. 450.Google Scholar
  76. 76.
    M.A. Bruck, R. Bav, M. Noji, K. Inagaki and Y. Kidani, Inorg. Chim. Acta 92 (1984) 279.CrossRefGoogle Scholar
  77. 77.
    A.R. Khokhar, G. Lumetta and S.L. Doran, Inorg. Chim. Acta 151 (1988) 87.CrossRefGoogle Scholar
  78. 78.
    Y. Kidani, in Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy, ed. M. Nicolini, Martinus Nijhoff, Boston, MA (1988) p. 555.Google Scholar
  79. 79.
    W.K. Anderson, D.A. Quagliato, R.D. Haugwitz, V.L. Narayanan and M.K. Wolpert-DeFilippes, Cancer Treat. Rep. 70 (1986) 997.Google Scholar
  80. 80.
    B.R. Vishnuvajjala, U.S. Patent Applic. 780,932, 1985.Google Scholar
  81. 81.
    W.K. Anderson and D.A. Quagliato, U.S. Patent. 4,550,187, 1985.Google Scholar
  82. 82.
    A. Eastman, Biochem. Pharmacol. 36 (1987) 4177.CrossRefGoogle Scholar
  83. 83.
    L.S. Hollis, A.R. Amundsen and E.W. Stern, J. Am. Chem. Soc. 107 (1985) 274.CrossRefGoogle Scholar
  84. 84.
    R. Perez-Soler, A.R. Khokhar, M.P. Hacker and G. Lopez-Berestein, Cancer Res. 46 (1986) 6269.Google Scholar
  85. 85.
    T.H. Corbett, F.A. Valeriote and L.H. Baker, Invest. New Drugs 5 (1987) 3.CrossRefGoogle Scholar

Copyright information

© Blackie & Son Ltd 1990

Authors and Affiliations

  • M. J. Abrams

There are no affiliations available

Personalised recommendations